Share
As the COVID-19 pandemic became more serious, the Endocrine Society joined a coalition of bone health organizations that united to issue new osteoporosis treatment guidelines. Aside from addressing the challenges social distancing has placed on treating these patients, the coalition has also focused on the administration of osteoporosis medications including denosumab, teriparatide, abaloparatide, romosozumab, and...
Share
Therapies that can extend the life of cancer patients often have a negative impact on the skeleton, especially in those being treated for hormone-sensitive cancers. Evidence shows improvements in bone health when bisphosphonates and denosumab are administered. Patients diagnosed with cancer are living longer, with some unanticipated ramifications. According to Facts & Figures 2018, published...
Share
Artificial intelligence that can “read” electronic radiology reports and flag patients with broken bones who are at risk of osteoporosis outperformed the traditional manual method of health care professionals reading X-ray reports, a new study finds. The results were presented during a virtual news conference hosted by the Endocrine Society. The new search tool, called...
Share
New recommendations include romosozumab therapy for high risk patients The Endocrine Society today announced an update to its osteoporosis Clinical Practice Guideline to include recommendations for romosozumab, a new medication that was approved last year to treat postmenopausal women at high risk of fracture. The U.S. Food and Drug Administration approved romosozumab in April 2019,...
Share
Vitamin D enthusiasts have long promoted high doses to obtain hoped-for benefits, but clinical trials are not finding them. Clinical trials of high doses of vitamin D are not finding the benefits that some advocates had promoted and are even hinting at some adverse effects. “The enthusiasm for high-dose vitamin D has certainly outpaced the...
